Recent blog posts
Lutikizumab Shows Promise in Phase 2 Trial for Moderate to Severe Hidradenitis Suppurativa, Advances to Next Study Phase
Latest Hotspot
3 min read
Lutikizumab Shows Promise in Phase 2 Trial for Moderate to Severe Hidradenitis Suppurativa, Advances to Next Study Phase
15 January 2024
Lutikizumab Demonstrates Encouraging Outcomes in Phase 2 Study Among Individuals with Moderate to Advanced Hidradenitis Suppurativa, Progressing to Next Trial Stage.
Read →
Innovent announced Mazdutide's successful early Phase 3 trial in overweight and obese Chinese adults
Latest Hotspot
3 min read
Innovent announced Mazdutide's successful early Phase 3 trial in overweight and obese Chinese adults
13 January 2024
Innovent declared the successful completion of the initial stage 3 clinical evaluation for Mazdutide among overweight and obese adults in China.
Read →
EU Grants Authorization for New Eylea™ 8 mg Formulation
Latest Hotspot
3 min read
EU Grants Authorization for New Eylea™ 8 mg Formulation
13 January 2024
The EU Commission has approved Eylea™ 8 mg, an 8 mg aflibercept (114.3 mg/ml) injectable, for treating neovascular age-related macular degeneration and diabetic macular edema-related vision loss.
Read →
Bayer's new drug elinzanetant successfully achieves main and critical additional goals in essential OASIS 1 and 2 Phase III trials
Latest Hotspot
3 min read
Bayer's new drug elinzanetant successfully achieves main and critical additional goals in essential OASIS 1 and 2 Phase III trials
13 January 2024
Bayer announced positive early results from Phase III OASIS 1 and 2 trials, where the experimental drug elinzanetant outperformed placebo.
Read →
Curevo Vaccine's Phase 2 study shows Amezosvatein, a new shingles vaccine, is effective compared to Shingrix
Latest Hotspot
3 min read
Curevo Vaccine's Phase 2 study shows Amezosvatein, a new shingles vaccine, is effective compared to Shingrix
13 January 2024
Curevo Vaccine has reported its second-phase study for Amezosvatein, This advanced shingles immunization demonstrates effectiveness against Shingrix in direct comparison.
Read →
OKYO Pharma Corp. reports that OK-101 hit key efficacy goals in its Phase 2 trials, effectively treating dry eye syndrome
Latest Hotspot
3 min read
OKYO Pharma Corp. reports that OK-101 hit key efficacy goals in its Phase 2 trials, effectively treating dry eye syndrome
13 January 2024
OKYO Pharma Corporation has disclosed that OK-101 has met its primary efficacy benchmarks in Phase 2 human trials, demonstrating statistical relevance in treating dry eye condition.
Read →
Scemblix® by Novartis shows superior efficacy in a Phase III trial, significantly increasing molecular remission rates for new chronic myeloid leukemia cases
Latest Hotspot
3 min read
Scemblix® by Novartis shows superior efficacy in a Phase III trial, significantly increasing molecular remission rates for new chronic myeloid leukemia cases
13 January 2024
Novartis' Scemblix® outperforms traditional therapy in achieving significant molecular remission in a Phase III study involving newly diagnosed chronic myeloid leukemia patients.
Read →
Caliway Announces FDA Phase II Trial Approval for Dercum's Syndrome Candidate CBL-514
Latest Hotspot
3 min read
Caliway Announces FDA Phase II Trial Approval for Dercum's Syndrome Candidate CBL-514
13 January 2024
Caliway Reveals US FDA Approval for Phase II Trial Application of CBL-514, a Sham-Controlled Study Aiming to Address Dercum's Syndrome.
Read →
UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
Latest Hotspot
3 min read
UCB announces EU approval for RYSTIGGO as an adult generalized myasthenia gravis treatment
13 January 2024
UCB has revealed that the European Commission has sanctioned the use of RYSTIGGO (rozanolixizumab) for treating generalized myasthenia gravis in adult patients across Europe.
Read →
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
Latest Hotspot
3 min read
OBI Pharma announced FDA approval for a Phase 1/2 trial of its TROP2 ADC, OBI-992
13 January 2024
OBI Pharma has disclosed that the FDA has given its approval for a Phase 1/2 clinical trial application concerning OBI-992, a TROP2 antibody-drug conjugate.
Read →
AskBio Commences Phase 2 Clinical Study of GenePHIT in Heart Failure Treatment
Latest Hotspot
3 min read
AskBio Commences Phase 2 Clinical Study of GenePHIT in Heart Failure Treatment
13 January 2024
Asklepios BioPharmaceutical, Inc., a wholly-owned subsidiary of Bayer AG, has launched Phase II of the GenePHIT trial to assess the effectiveness of its gene therapy drug AB-1002 (NAN-101) for congestive heart failure.
Read →
Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
Latest Hotspot
3 min read
Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
13 January 2024
Sana Biotech Reveals US Regulatory Approval for Experimental Drug SC262, an Engineered Immune-resistant, Targeted CD22 Allo CAR T Cell Treatment, Aimed at Individuals Suffering from Recurring or Resistant Types of B-cell Cancer.
Read →